Patents Examined by Craig Ricci
  • Compounds for nonsense suppression, and methods for their use
    Patent number: 9273076
    Abstract: The present invention relates to methods, compounds, and compositions for treating or preventing diseases associated with nonsense mutations in an mRNA by administering the compounds or compositions of the present invention. More particularly, the present invention relates to methods, compounds, and compositions for suppressing premature translation termination associated with a nonsense mutation in an mRNA.
    Type: Grant
    Filed: April 28, 2014
    Date of Patent: March 1, 2016
    Assignee: PTC Therapeutics, Inc.
    Inventors: Jeffrey A. Campbell, Atiyya Kahn, James Takasugi, Ellen Welch
  • Treatment of type 1 diabetes
    Patent number: 9271984
    Abstract: The present invention relates to triazine derivatives of formula (I) for their use in the treatment of type 1 diabetes mellitus, and to compositions comprising said triazine derivatives.
    Type: Grant
    Filed: June 9, 2011
    Date of Patent: March 1, 2016
    Assignee: POXEL
    Inventors: Pascale Fouqueray, Daniel Cravo, Sophie Hallakou-Bozec, Sébastien Bolze
  • Use of oxycodone for treating visceral pain
    Patent number: 9271974
    Abstract: It is possible to effectively treat moderate to severe visceral pain by administering analgesic medications comprising the opioid oxycodone or pharmaceutically acceptable salts thereof. Visceral pain and especially acute (i.e. non-chronic) visceral pain can be effectively treated by administering oxycodone at a dosage which is lower than the corresponding dosage of the other opioids like morphine.
    Type: Grant
    Filed: October 15, 2014
    Date of Patent: March 1, 2016
    Assignee: PURDUE PHARMA L.P.
    Inventors: Asbjorn Mohr Drewes, Lars Arendt Nielsen
  • Phthalazinone ketone derivative, preparation method thereof, and pharmaceutical use thereof
    Patent number: 9273052
    Abstract: A phthalazinone ketone derivative as represented by formula (I), a preparation method thereof, a pharmaceutical composition containing the derivative, a use thereof as a poly (ADP-ribose) polymerase (PARP) inhibitor, and a cancer treatment method thereof are described.
    Type: Grant
    Filed: July 26, 2011
    Date of Patent: March 1, 2016
    Assignee: Jiangsu Hansoh Pharmaceutical Co., Ltd.
    Inventors: Peng Cho Tang, Xin Li, Xiangqin Li, Yang Chen, Bin Wang, Zhe Zhu
  • 5?-androstane-3?,5,6?-triol injection and preparation method therefor
    Patent number: 9265837
    Abstract: A 5?-androstane-3?,5,6?-triol injection and its preparation are disclosed. The injection uses hydroxypropyl-?-cyclodextrin as a solubilizing agent and the active ingredient is present at a weight ratio of 1-20:40-500 to the hydroxypropyl-?-cyclodextrin. The injection may also comprise, by weight, 1-100 parts of at least one isotonic adjusting agent, 0-200 parts of at least one freeze drying filler, and 0-2000 parts of at least one solvent. The preparation method comprises dissolving hydroxypropyl-?-cyclodextrin solution, 5?-androstane-3?,5,6?-triol and at least one additional soluble excipient in water for injection in sequence to obtain a raw injection solution, and subjecting the raw injection solution to decolorization, depyrogenation, filtration and sterilization to obtain the injection. Drying the filtrate yields a solid for injection.
    Type: Grant
    Filed: August 28, 2015
    Date of Patent: February 23, 2016
    Assignee: Guangzhou Cellprotek Pharmaceuticals Ltd.
    Inventors: Guangmei Yan, Haiyan Hu, Jingxia Zhang, Pengxin Qiu, Ling Li, Ning Tian
  • Composition for promoting vascular smooth muscle relaxation
    Patent number: 9265721
    Abstract: A composition for topical application to a part of the body comprises a local anaesthetic and optionally a vasodilator as active ingredient dissolved in a blend of volatile and non-volatile solvents of different solvating capacities for the active ingredient. The vasodilator may comprise glyceryl trinitrate and the local anaesthetic may comprises an anaesthetic of the aminoamide or aminoester type. The volatile solvent may comprise a mixture of water with a C1-C5 alcohol and the non-volatile solvent may comprise a polyhydric alcohol and optionally a glycol. A low-concentration vasodilator-containing composition is also described. The compositions allow a “virtual injection” of the active ingredient to be delivered transdermally without general systemic uptake.
    Type: Grant
    Filed: January 23, 2007
    Date of Patent: February 23, 2016
    Assignee: FUTURA MEDICAL DEVELOPMENTS LIMITED
    Inventor: Adrian Francis Davis
  • Tricyclic compounds and methods of making and using same
    Patent number: 9266896
    Abstract: The invention provides tricyclic compounds and their use in treating medical disorders, such as obesity. Pharmaceutical compositions and methods of making various tricyclic compounds are provided. The compounds are contemplated to have activity against methionyl aminopeptidase 2.
    Type: Grant
    Filed: July 21, 2011
    Date of Patent: February 23, 2016
    Assignee: Zafgen, Inc.
    Inventors: David Clark, Susan Mary Cramp, Hazel Joan Dyke, Thomas David Pallin, Robert Zahler
  • Composite material consisting of a collagen matrix mineralised with silicate and calcium phosphate phases, method for the production and use thereof
    Patent number: 9265861
    Abstract: The invention relates to novel composite materials based on a collagen matrix mineralized with silicate and calcium phosphate phases, to a method for the production thereof and use thereof as an implant material which can be shaped in a plurality of ways, a biological coating or active substance carrier. The claimed composite material comprises a collagen matrix which is mineralized with silicate and a calcium phosphate phase, said collagen being a recombinate collagen, collagen from Eumetazoa, sponge collagen from a sponge of the Demospongia class (horn sponges) or Calcarea (calcareous sponges), a synthetic collage analog, a collagen derivative or a mixture of said collagens.
    Type: Grant
    Filed: September 11, 2009
    Date of Patent: February 23, 2016
    Assignee: Technische Universität Dresden
    Inventors: Sascha Heinemann, Hartmut Worch, Thomas Hanke
  • Urea compounds and use thereof for inhibiting apoptosis
    Patent number: 9260384
    Abstract: A compound of Formula I, or an isomer, pharmaceutically acceptable salt or solvate thereof, is provided. Also, a composition containing a compound of Formula I, or an isomer, pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable carrier, excipient or diluents, is provided. Further, use of a compound of Formula I, or an isomer, pharmaceutically acceptable salt or solvate thereof for anti-apoptosis is provided, preventing or treating a disease or disorder associated with apoptosis; especially for protecting cardiomyocyte, preventing or treating a disease or disorder associated with cardiomyocyte apoptosis.
    Type: Grant
    Filed: May 14, 2010
    Date of Patent: February 16, 2016
    Assignee: Chinese PLA General Hospital
    Inventors: Kunlun He, Song Li, Wu Zhong, Juan Liu, Lili Wang, Xin Li, Guoliang Hu, Long Long, Junhai Xiao, Zhibing Zheng, Wei Li, Ruijun Li, Chunlei Liu, Jie Bai
  • Anti-aging composition containing phloretin
    Patent number: 9248082
    Abstract: An anti-aging composition containing: (a) at least one first active ingredient chosen from phloretin and its derivatives; (b) at least one second active ingredient chosen from cinnamic acid, resveratrol, retinol, ascorbic acid, tocopherol, and their derivatives; and (c) at least one non-aqueous organic solvent, with the proviso that if the composition contains ascorbic acid, water is present as a co-solvent.
    Type: Grant
    Filed: April 15, 2009
    Date of Patent: February 2, 2016
    Assignee: L'OREAL
    Inventors: Sheldon R. Pinnell, Jan Zielinski, Isabelle Hansenne
  • Preparation and uses of obeticholic acid
    Patent number: 9238673
    Abstract: The present invention relates to obeticholic acid: or a pharmaceutically acceptable salt, solvate or amino acid conjugate thereof. Obeticholic acid is useful for the treatment or prevention of a FXR mediated disease or condition, cardiovascular disease or cholestatic liver disease, and for reducing HDL cholesterol, for lowering triglycerides in a mammal, or for inhibition of fibrosis. The present invention also relates to processes for the synthesis of obeticholic acid.
    Type: Grant
    Filed: June 17, 2013
    Date of Patent: January 19, 2016
    Assignee: Intercept Pharmaceuticals, Inc.
    Inventors: André Steiner, Heidi Waenerlund Poulsen, Emilie Jolibois, Melissa Rewolinski, Ralf Gross, Emma Sharp, Fiona Dubas-Fisher, Alex Eberlin
  • Methods of treating lysosomal storage disorders
    Patent number: 9233083
    Abstract: Therapeutic compositions and methods for treatment of late-onset Gaucher disease are described herein. The compositions comprise compounds having activity as pharmacological chaperones for mutant forms of the beta-glucocerebrosidase. Methods of treatment involve providing therapeutically effective amounts of such compositions to subjects in need thereof.
    Type: Grant
    Filed: April 17, 2014
    Date of Patent: January 12, 2016
    Assignees: The Hospital for Sick Children, McMaster University
    Inventors: Don J. Mahuran, Michael B. Tropak, Justin D. Buttner, Jan E. Blanchard, Eric D. Brown
  • Therapeutic agent for lower urinary tract disease
    Patent number: 9226926
    Abstract: A method of treating a condition chosen from the group consisting of interstitial cystitis, cystitis, chronic nonbacterial prostatitis, chronic cystitis, prostatic hyperplasia, prostatitis, prostatism, bladder neck contracture, bladder inflammation, and overactive bladder by administering an amount of rebamipide or a pharmaceutically acceptable salt thereof to a human.
    Type: Grant
    Filed: December 26, 2013
    Date of Patent: January 5, 2016
    Assignee: N.M.A. CO., LTD.
    Inventors: Tomohiro Ueda, Yasuhito Funahashi
  • Beneficial effects of increasing local blood flow
    Patent number: 9226909
    Abstract: The present invention generally relates to the improvement of tissue health by increasing local blood flow. In some aspects of the invention, increased local blood flow is effected by the transdermal delivery of the nitric oxide precursor L-arginine and/or its derivatives alone, or optionally in conjunction with an adjunct such as theophylline. The transdermal delivery is effected, in certain embodiments through the means of a hostile biophysical environment, such as that created by a high ionic strength environment. Various pathological states caused by, or occurring in conjunction with, insufficient blood flow, can be treated using the systems and methods of the invention as described herein. In other embodiments, increased blood flow using the systems and methods of the invention may result in enhanced healing, for example, through greater availability of the constituents of the blood.
    Type: Grant
    Filed: April 10, 2013
    Date of Patent: January 5, 2016
    Assignee: Strategic Science & Technologies, LLC
    Inventor: Eric T. Fossel
  • Oligomer modified diaromatic substituted compounds
    Patent number: 9226970
    Abstract: Disclosed are compounds comprising diaromatic substituted compound residues, namely the anti-viral (anti-HIV) drug delavirdine, covalently attached via a linkage to water-soluble, non-peptidic oligomers, specifically to poly(ethylene glycol) (PEG) oligomers. A compound of the invention, when administered by any of a number of administration routes, exhibits advantages over non-oligomer modified diaromatic substituted compounds.
    Type: Grant
    Filed: February 22, 2011
    Date of Patent: January 5, 2016
    Assignee: Nektar Therapeutics
    Inventors: Jennifer Riggs-Sauthier, Bo-Liang Deng
  • Compounds for the treatment of pathologies associated with aging and degenerative disorders
    Patent number: 9220711
    Abstract: The present invention relates to methods of inhibiting one or more signs of aging and/or degenerative disorder in a subject in need of such treatment, which comprise administering, to the subject, an effective amount of one or more of the compounds as set forth herein. “Inhibiting a sign of aging or degenerative disorder” means reducing the risk of occurrence, delaying the onset, slowing the progression, and/or reducing the severity and/or manifestation, of a sign of aging or degenerative disorder, and includes, but is not limited to, preventing the occurrence, development or progression of a sign of aging or degenerative disorder.
    Type: Grant
    Filed: March 18, 2014
    Date of Patent: December 29, 2015
    Assignee: University of Pittsburgh—of the Commonwealth System of Higher Education
    Inventors: Laura J. Niedernhofer, Paul D. Robbins, Peter Wipf
  • Shapeable bone graft substitute and instruments for delivery thereof
    Patent number: 9220595
    Abstract: Injectable bone graft material having a biocompatible, resorbable polymer and a biocompatible, resorbable inorganic material exhibiting macro, meso, and microporosities.
    Type: Grant
    Filed: June 23, 2004
    Date of Patent: December 29, 2015
    Assignee: Orthovita, Inc.
    Inventors: Charanpreet S. Bagga, Theodore D. Clineff, Erik M. Erbe, Michael W. Paris, Gina M. Nagvajara, Antony Koblish
  • Photolabile fragrance storage substances
    Patent number: 9217126
    Abstract: Photolabile fragrance storage substances capable of photo-induced release of odorant aldehydes and odorant ketones are described in addition to a process for long-lasting fragrancing of surfaces and a process for producing said fragrance storage substances.
    Type: Grant
    Filed: June 9, 2011
    Date of Patent: December 22, 2015
    Assignee: Henkel AG & Co. KGaA
    Inventors: Ursula Huchel, Christian Kropf, Axel Griesbeck, Olga Hinze, Uta Sundermeier
  • Injectable preparations of diclofenac and its pharmaceutically acceptable salts
    Patent number: 9211251
    Abstract: Injectable formulations of water-soluble salts of diclofenac, which cause significantly less pain at the site of injection and can be administered by intradeltoid route, in addition to intragluteal and slow intravenous route.
    Type: Grant
    Filed: January 25, 2013
    Date of Patent: December 15, 2015
    Assignee: TROIKAA PHARMACEUTICALS LIMITED
    Inventors: Ketan Rajnibhai Patel, Milan Rajnibhai Patel
  • Aqueous ophthalmic suspension of crystalline rebamipide
    Patent number: 9211254
    Abstract: The invention provides an ophthalmic product containing rebamipide, which has a transparency enough to be agreeable feeling on using it and has neutral to weakly acidic pH not to injury of the keratoconjunctiva of a patient suffering from dry eye. An aqueous suspension of crystalline rebamipide which has an improved transparency is provided by adding an aqueous solution of rebamipide dissolved by a base such as sodium hydroxide or an aqueous solution of a salt of rebamipide to an aqueous acidic solution such as hydrochloric acid containing at least one of the compounds selected from water-soluble polymers and surfactants, and mixing them.
    Type: Grant
    Filed: November 11, 2005
    Date of Patent: December 15, 2015
    Assignee: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Takakuni Matsuda, Shogo Hiraoka, Yuso Tomohira, Shinichi Ishikawa